Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27082996 | 0.83 | HRH4 (0.59) | HRH4KMT2AHTR3A | |
| SCHEMBL20604725 | 0.83 | KMT2A (0.56) | HRH4KMT2ANPSR1TP53HSD17B10 | |
| SCHEMBL26037956 | 0.83 | HRH4 (0.61) | HRH4KMT2AHTR3A | |
| SCHEMBL15246924 | 0.81 | ALDH1A1 (0.52) | KMT2ATP53 | |
| SCHEMBL23809147 | 0.79 | HRH4 (0.53) | HRH4KMT2ANPSR1TP53HSD17B10 | |
| SCHEMBL22924654 | 0.79 | HRH4 (0.74) | HRH4KMT2ANPSR1TP53HSD17B10 | |
| SCHEMBL12257800 | 0.79 | HRH4 (0.74) | HRH4KMT2ANPSR1TP53HSD17B10 | |
| SCHEMBL20604872 | 0.78 | HRH4 (0.47) | HRH4KMT2ANPSR1TP53HSD17B10 | |
| SCHEMBL8171578 | 0.76 | HRH4 (0.65) | HRH4KMT2ANPSR1HSD17B10HTR3A | |
| SCHEMBL9488077 | 0.76 | HRH1 (0.59) | KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | HRH4 4602/4885KMT2A 824/4885NPSR1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.